Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Chronic lymphocytic leukemia (CLL)
Trial Type:  Treatment
Treatment/Intervention:  allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, high-dose chemotherapy, bone marrow transplantation, autologous bone marrow transplantation
Trial Status:  Active
Trial Phase:  Phase II, Phase III
Results 1-14 of 14 for your search:
Start Over
Mature B-Cell Lymphoma And Leukemia Study III
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: SJBC3, NCT01046825
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 040055, 04-C-0055, NCI-04-C-0055, NCT00077480, NCT00074490
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: 1999LS060, 9909M18181, UMN-MT1999-14, UMN-1999LS060, NCT00612716
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2241.00, NCI-2009-01334, P30CA015704, NCT01008462
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCI-2011-03144, NCT01010217
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCW 11491, NCT01050946
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-304, NCCN Protocol Number: NCCN-001, GSK Protocol Number: OFT115580, NCT01465334
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16622, GSK OFT114879, RV-CLL-PI-0560, NCT01496976
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LLC1215, 2015-000684-13, NCT02388048
Start Over